Last checked at 1 Feb 2021 07:00
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum to Present at the LSX World Congress 2021
Cambridge, UK, 1 February 2021 - Sareum Holdings plc (AIM:SAR), the specialist small molecule drug development business, announces that its CEO, Dr Tim Mitchell, will give a Company presentation at the 7th Annual LSX World Congress, which will be delivered digitally between 1 and 5 February 2021.
The presentation will showcase Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively. Dr Mitchell will also highlight the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections.
The presentation will be made through the conference website and will be available to registered participants throughout the event - www.lsxleaders.com/lsx-world-congress
A copy of the presentation will also be made available on Sareum's website - www.sareum.com
For further information, please contact:
Sareum Holdings plc Tim Mitchell, CEO
|
01223 497 700 |
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
Hybridan LLP (Nominated Broker) Claire Noyce / John Beresford-Peirse
|
020 3764 2341 |
Citigate Dewe Rogerson (Financial PR) Mark Swallow/ David Dible |
020 7638 9571 |
About LSX World Congress
LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life sciences giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.
The industry's c-suite will be joined by the sector's most active investors, pharma and health tech BD&L teams, R&D leaders, KOLs and top tier service companies who are moving the sector forward.
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com